This year, the popularity of public fund participation in fixed increase has dropped significantly.
According to Wind statistics, the total cost of public fund participation in fixed increase in the same period last year exceeded 60 billion yuan
.
As of August 24 this year, the fund has participated in the private placement of 89 listed companies during the year, with a total participation cost of 36.
113 billion yuan
.
However, analysts pointed out that while the participation of public funds is declining, they are more cautious in the choice of fixed growth industries, and they are mostly concentrated in popular tracks such as new energy and medicine
.
It is reported that public funds have repeatedly "scrambled for money" in the pharmaceutical industry's private placement
.
For example, on July 26, Fosun Pharma's fixed increase announcement showed that the total amount of funds raised in this fixed increase was 4.
484 billion yuan, and the four public funds of Caitong, Dacheng, Huaxia and China Merchants were allocated 570 million yuan and 148 million yuan respectively.
yuan, 131 million yuan and 102 million yuan, accounting for more than 20% of the investment
.
The announcement shows that this fundraising project includes preparations for the clinical trial of innovative drugs, licensing introduction and product listing, the construction of an intensive and comprehensive base for raw materials and preparations, and the supplement of working capital; it is planned to invest 1.
874 billion yuan, 1.
349 billion yuan and 1.
26 billion yuan
.
In the field of innovative drugs, Fosun Pharma’s fixed increase involves a total of 11 sub-projects, including FCN-437, ferric citrate pyrophosphate solution (Triferic), FS-1502, FCN-159, and liraglutide
.
In the field of APIs, this fundraising project is positioned as a comprehensive production base for intensive, large-capacity product manufacturing and innovative drugs and special preparations
.
In addition, public funds have also appeared many times in the fixed increase allocation list of pharmaceutical companies such as Nano Micro Technology, OPCOM, and Common People
.
For example, on July 1, Nanowei Technology announced that the company issued 3,025,900 shares to specific objects, and the actual fundraising was 197 million yuan
.
The GF Fund was allocated a total of 635,800 shares, with an allocation amount of 41.
3426 million yuan; Caitong Fund was allocated 353,700 shares, with an allocation amount of 23 million yuan
.
The announcement shows that Nano Micro Technology has raised 197 million yuan this time, of which 113 million yuan is planned to be used to acquire part of the equity of Sepu Instruments, and 29.
54 million yuan is planned to be used for Changshu Nano Micro to eliminate 1,000 tons/year light diffusion The technical transformation project of particle reduction and replacement to produce 40 tons/year of agarose microspheres and 10 tons/year of dextran microspheres chromatography medium, and the fundraising of 54 million yuan is planned to be used to supplement working capital
.
OPCOM announced on June 7 that the company issued 42,594,826 ordinary shares to 13 specific investors, raising a total of 1.
503 billion yuan, of which Nord Fund was allocated about 248 million yuan; Huaxia Fund was allocated about 133 million yuan; Caitong Fund was allocated about 106 million yuan
.
It is reported that this fixed increase is the first time that OPCOM has refinanced since its listing in 2017
.
According to the plan, the company plans to use the raised funds to invest in the industrialization project of contact lenses and supporting products, and the construction project of community-based optometry service terminal
.
In February, the common people disclosed the results of the fixed increase.
The fixed increase raised 1.
74 billion yuan in full.
In this fixed increase, public fund companies such as Cathay Pacific Fund, China Asset Management, and E Fund Fund were included
.
According to the announcement, the investment funds raised by the common people company will be used for the new chain pharmacy project, the Huadong pharmaceutical product sorting and processing project, the enterprise digital platform and the new retail construction project
.
According to statistics, as of now, the actual amount of funds raised by fixed increase during the year is far less than that of the same period last year.
Taking the issue date as the statistical standard, as of August 24, a total of 171 listed companies have implemented private placement this year, compared with 313 in the same period last year.
This year, the total amount of funds raised by fixed increase was 344.
450 billion yuan, compared with 447.
312 billion yuan in the same period last year
.
However, from the perspective of the whole year, industries such as medicine are still the focus of public offering institutions
.
